545 ATX/LPA upregulation via microRNA-29 loss suppresses cytotoxic T cells and promotes resistance to anti-PD-1 in non-small cell lung cancer

Jessica Konen(Emory University), Don L. Gibbons(The University of Texas MD Anderson Cancer Center), B. Leticia Rodriguez(The University of Texas MD Anderson Cancer Center), Laura Gibson(The University of Texas MD Anderson Cancer Center), Jared J. Fradette(The University of Texas MD Anderson Cancer Center), Lixia Diao(The University of Texas MD Anderson Cancer Center), Jianjun Zhang(The University of Texas MD Anderson Cancer Center), Jing Wang(NYU Langone Health), Stephanie Schmidt, Haoyi Wu(The University of Texas MD Anderson Cancer Center), Ignacio I. Wistuba(The University of Texas MD Anderson Cancer Center)
Regular and Young Investigator Award Abstracts
October 31, 2023
10.1136/jitc-2023-sitc2023.0545
Cited by 0

Related Papers

International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society International Multidisciplinary Classification of Lung Adenocarcinoma
|Journal of Thoracic Oncology|2011|4.8k
PD-L1 as a biomarker of response to immune-checkpoint inhibitors
|Nature Reviews Clinical Oncology|2021|1.5k
Avelumab Maintenance Therapy for Advanced or Metastatic Urothelial Carcinoma
|New England Journal of Medicine|2020|1.5k
Local Consolidative Therapy Vs. Maintenance Therapy or Observation for Patients With Oligometastatic Non–Small-Cell Lung Cancer: Long-Term Results of a Multi-Institutional, Phase II, Randomized Study
|Journal of Clinical Oncology|2019|1.3k
Local consolidative therapy versus maintenance therapy or observation for patients with oligometastatic non-small-cell lung cancer without progression after first-line systemic therapy: a multicentre, randomised, controlled, phase 2 study
|The Lancet Oncology|2016|1.1k